MX2017013337A - Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia. - Google Patents

Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia.

Info

Publication number
MX2017013337A
MX2017013337A MX2017013337A MX2017013337A MX2017013337A MX 2017013337 A MX2017013337 A MX 2017013337A MX 2017013337 A MX2017013337 A MX 2017013337A MX 2017013337 A MX2017013337 A MX 2017013337A MX 2017013337 A MX2017013337 A MX 2017013337A
Authority
MX
Mexico
Prior art keywords
delivery system
insulin
sensitive
glucose
vesicles
Prior art date
Application number
MX2017013337A
Other languages
English (en)
Other versions
MX381766B (es
Inventor
Gu Zhen
Yu Jicheng
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Publication of MX2017013337A publication Critical patent/MX2017013337A/es
Publication of MX381766B publication Critical patent/MX381766B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)

Abstract

Se describe un sistema de suministro de insulina de bucle cerrado. De forma más particular, el sistema de suministro de insulina que ahora se desvela pude comprender vesículas sensibles a glucosa que liberan insulina en respuesta a la hipoxia desencadenada por la reducción enzimática de glucosa. Además o como alternativa a la insulina, el sistema de suministro puede liberar otros agentes de tratamiento de la diabetes, tales como agentes de tratamiento de la diabetes no basados en insulina. Las vesículas pueden prepararse a partir de un polímero sensible a la hipoxia, tal como un ácido hialurónico sensible a la hipoxia (AH-SH). El AH-SH puede comprender grupos hidrofóbicos que pueden reducirse en entornos hipóxicos para formar grupos hidrófilos. Las vesículas pueden cargarse en microagujas y parches de matriz de microagujas para su uso en el tratamiento de la diabetes o para regular de otro modo los niveles de glucosa en sangre en sujetos que necesiten tal tratamiento.
MX2017013337A 2015-04-21 2016-04-21 Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia. MX381766B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150622P 2015-04-21 2015-04-21
PCT/US2016/028605 WO2016172320A1 (en) 2015-04-21 2016-04-21 Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites

Publications (2)

Publication Number Publication Date
MX2017013337A true MX2017013337A (es) 2018-04-20
MX381766B MX381766B (es) 2025-03-11

Family

ID=57144247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013337A MX381766B (es) 2015-04-21 2016-04-21 Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia.

Country Status (21)

Country Link
US (2) US11191815B2 (es)
EP (2) EP3285750B1 (es)
JP (1) JP6856546B2 (es)
KR (1) KR102624501B1 (es)
CN (2) CN107530296B (es)
AU (2) AU2016252738B2 (es)
BR (1) BR112017022535A2 (es)
CA (1) CA2983289C (es)
CL (1) CL2017002652A1 (es)
CO (1) CO2017011422A2 (es)
DO (1) DOP2017000239A (es)
EC (1) ECSP17073558A (es)
IL (1) IL255155A0 (es)
MA (1) MA54623A (es)
MX (1) MX381766B (es)
PE (1) PE20180325A1 (es)
PH (1) PH12017501910A1 (es)
RU (1) RU2719584C2 (es)
SG (1) SG11201708509YA (es)
TN (1) TN2017000439A1 (es)
WO (1) WO2016172320A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000439A1 (en) 2015-04-21 2019-04-12 Univ North Carolina State Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
JP7202890B2 (ja) * 2016-02-19 2023-01-12 ノース カロライナ ステート ユニバーシティ 生理学的応答性マイクロニードル送達システムに関連する方法及び組成物
CN110167537A (zh) * 2016-11-07 2019-08-23 北卡罗来纳州立大学 用于增强葡萄糖反应性胰岛素的递送的装有双敏感囊泡的贴剂
DK3548135T3 (da) * 2016-12-05 2021-11-22 Univ North Carolina State Kerne-skal-mikronålsindretninger og anvendelser deraf
CN110198730B (zh) 2016-12-05 2023-10-03 北卡罗莱纳州立大学 H2o2响应性纳米粒子及其用途
WO2018165294A1 (en) 2017-03-07 2018-09-13 North Carolina State University Insulin-responsive glucagon delivery patch
EP3634470A4 (en) * 2017-06-02 2021-03-10 North Carolina State University GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG ADMINISTRATION
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
WO2019055901A1 (en) 2017-09-18 2019-03-21 North Carolina State University ARTIFICIAL β CELLS AND METHODS OF USE
CN111447942A (zh) * 2017-10-10 2020-07-24 北卡罗莱纳州立大学 用于葡萄糖响应性胰岛素递送的经葡萄糖转运蛋白抑制剂修饰的胰岛素
US11813352B2 (en) 2017-11-21 2023-11-14 North Carolina State University Charge-switchable polymeric depot for glucose-triggered insulin delivery with ultrafast response
CN108484848A (zh) * 2018-02-27 2018-09-04 同济大学 一种缺氧响应的聚合物纳米胶束及其制备方法
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用
CN108395489A (zh) * 2018-03-22 2018-08-14 华侨大学 一种2-硝基咪唑-半胱氨酸-海藻酸盐材料及其制备方法
US20210145984A1 (en) * 2018-04-13 2021-05-20 North Carolina State University Ros-responsive microneedle patch for acne vulgaris treatment
US20210161968A1 (en) * 2018-04-13 2021-06-03 North Carolina State University Use of microneedle patch to promote hair growth
CN109464657A (zh) * 2018-11-26 2019-03-15 常州工程职业技术学院 一种嵌段共聚物载胰岛素控制释放的方法
CN109568567A (zh) * 2019-01-15 2019-04-05 武汉德丽福生物科技有限公司 一种微针减肥贴片及其制备方法
CN109771659A (zh) * 2019-02-25 2019-05-21 天津大学 一种乏氧响应性纳米药物载体及其制备方法和应用
CN110652494B (zh) * 2019-10-21 2021-09-28 南通大学 一种低氧响应聚氨基酸-peg立构载药胶束及其制备方法
CN110841065A (zh) * 2019-12-05 2020-02-28 福州大学 一种pH/低氧双响应释药协同光动力治疗的纳米复合物及其制备方法
JP2023523952A (ja) 2020-04-28 2023-06-08 ティコナ・エルエルシー マイクロニードルアセンブリ
CN115317437B (zh) * 2021-05-11 2023-09-08 中国科学院上海硅酸盐研究所 一种基于胆红素纳米材料的胰岛素递送微针及其制备方法
CN114376569B (zh) * 2022-01-19 2023-10-13 浙江大学 用于救治低血糖的载胰高血糖素可穿戴设备
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用
CN115120552B (zh) * 2022-06-22 2024-06-04 华中科技大学 一种微环境响应释药的多肽载药微针贴片、制备及应用
CN115531309B (zh) * 2022-09-29 2023-08-22 中国药科大学 一种肝靶向聚合物胶束递药系统及其制备方法和应用
CN115957317A (zh) * 2022-11-07 2023-04-14 浙江大学杭州国际科创中心 一种纳米疫苗及其制备方法
CN116942615A (zh) * 2023-08-25 2023-10-27 湖南师范大学 共递送紫杉醇和吉西他滨的纳米粒子及其制备方法与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
EP1610751A4 (en) * 2001-04-26 2006-05-24 Univ Texas THERAPEUTIC AGENT / LIGAND CONJUGATE COMPOSITIONS, ITS SYNTHESIS PROCESSES AND ITS APPLICATION
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
EP1469903A2 (en) * 2001-09-28 2004-10-27 BioValve Technologies, Inc. Microneedle with membrane
WO2003089506A1 (en) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
JP4185423B2 (ja) * 2003-09-09 2008-11-26 日本電信電話株式会社 電気化学バイオセンサの製造方法
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
CA2614927A1 (en) * 2005-07-25 2007-02-01 Nanotechnology Victoria Pty Ltd Microarray device
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2008011625A2 (en) * 2006-07-21 2008-01-24 Georgia Tech Researh Corporation Microneedle devices and methods of drug delivery or fluid withdrawal
CN101125086A (zh) * 2006-08-18 2008-02-20 刘胜 闭环自动控制胰岛素注射系统
EP2251006B1 (en) * 2008-02-22 2017-07-19 Toray Industries, Inc. Microparticles and pharmaceutical compositions thereof
US7775357B2 (en) 2008-04-14 2010-08-17 Asp Rights Management Pty Limited Syringe disposal device
KR20100037389A (ko) 2008-10-01 2010-04-09 연세대학교 산학협력단 다중 약물방출조절이 가능한 솔리드 마이크로구조체 및 이의 제조방법
DK2346563T3 (da) * 2008-10-07 2019-01-02 Tuo Jin Polymere faseovergangsmikronåle
WO2010088300A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
WO2010119409A1 (en) 2009-04-17 2010-10-21 Sensile Pat Ag Medical device for glucose monitoring or regulation
CN102039000B (zh) * 2009-10-20 2015-08-26 苏州纳通生物纳米技术有限公司 一种透皮给药试剂盒
WO2012050179A1 (ja) 2010-10-14 2012-04-19 シャープ株式会社 液晶表示装置の製造方法
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
WO2013123492A2 (en) * 2012-02-17 2013-08-22 Massachusetts Institute Of Technology Glucose-responsive microgels for closed loop insulin delivery
US20160067190A1 (en) * 2013-04-30 2016-03-10 The Children's Medical Center Corporation Injectable nano-network gels for diabetes treatment
KR102133889B1 (ko) * 2013-06-28 2020-07-14 엘지이노텍 주식회사 회로기판 및 상기 회로기판을 포함하는 조명장치
CN104353062A (zh) 2014-11-21 2015-02-18 中国人民解放军南京军区福州总医院 一种胰岛素口服纳米制剂及其制备方法
TN2017000439A1 (en) 2015-04-21 2019-04-12 Univ North Carolina State Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
US11141486B2 (en) 2015-10-23 2021-10-12 National University Corporation Tokyo Medical And Dental University Drug delivery device
JP7202890B2 (ja) 2016-02-19 2023-01-12 ノース カロライナ ステート ユニバーシティ 生理学的応答性マイクロニードル送達システムに関連する方法及び組成物
CN110167537A (zh) 2016-11-07 2019-08-23 北卡罗来纳州立大学 用于增强葡萄糖反应性胰岛素的递送的装有双敏感囊泡的贴剂

Also Published As

Publication number Publication date
EP3795143A1 (en) 2021-03-24
RU2017139931A3 (es) 2019-09-16
CA2983289C (en) 2023-10-03
IL255155A0 (en) 2017-12-31
PE20180325A1 (es) 2018-02-13
CN107530296A (zh) 2018-01-02
JP2018513874A (ja) 2018-05-31
WO2016172320A8 (en) 2017-11-02
MA54623A (fr) 2021-11-03
EP3285750A1 (en) 2018-02-28
ECSP17073558A (es) 2018-05-31
CL2017002652A1 (es) 2018-03-23
KR20170138542A (ko) 2017-12-15
BR112017022535A2 (pt) 2018-07-10
AU2016252738B2 (en) 2021-07-08
AU2016252738A1 (en) 2017-11-09
HK1245105A1 (zh) 2018-08-24
CN107530296B (zh) 2021-06-22
AU2021204048A1 (en) 2021-07-08
US20180110841A1 (en) 2018-04-26
TN2017000439A1 (en) 2019-04-12
CO2017011422A2 (es) 2018-03-28
US11191815B2 (en) 2021-12-07
SG11201708509YA (en) 2017-11-29
EP3285750B1 (en) 2020-10-21
NZ736578A (en) 2023-12-22
CN113350489A (zh) 2021-09-07
KR102624501B1 (ko) 2024-01-11
MX381766B (es) 2025-03-11
RU2017139931A (ru) 2019-05-21
CA2983289A1 (en) 2016-10-27
RU2719584C2 (ru) 2020-04-21
DOP2017000239A (es) 2018-01-15
WO2016172320A1 (en) 2016-10-27
JP6856546B2 (ja) 2021-04-07
US20220160841A1 (en) 2022-05-26
PH12017501910A1 (en) 2018-03-05
EP3285750A4 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
CO2017011422A2 (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
BR112014013151A2 (pt) dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir e usar o dispositivo
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
AR069704A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
WO2015105981A3 (en) Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
PH12015501931A1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
WO2015106295A3 (en) Enolase 1 (eno1) compositions and uses thereof
WO2015003122A3 (en) Regulation of glucose metabolism using anti-cgrp antibodies
PH12015502556A1 (en) Modified release formulation
CL2019003259A1 (es) Compuesto de insulina acilada.
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
PL419722A1 (pl) Zastosowanie medyczne kwasu kynureninowego i jego soli do zwolnienia akcji serca oraz zawierająca go kompozycja farmaceutyczna
TH172399A (th) การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน
EA202090988A1 (ru) Способы лечения синдрома фелан-макдермид с помощью дибензодиазепинонов фарнезила
HK1228762A1 (en) Rapid action insulin formulations and pharmaceutical delivery systems
Ozturk New onset diabetes mellitus post transplantation and diabetic ketoacidosis: case report
UA82542U (uk) Спосіб лікування хронічної серцевої недостатності з ознаками механічної десинхронізації у хворих на цукровий діабет 2 типу
HK1230955A1 (en) Cafestol for treating diabetes
PE20180326A1 (es) Formulaciones que contienen diacereina y metodos que las utilizan para disminuir el nivel del acido urico en sangre